A Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of the Oral Contraceptive YAZ (20 microg Ethinylestradiol, 3mg Drospirenone) for 13 Cycles in 670 Healthy Chinese Female Volunteers.

Trial Profile

A Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of the Oral Contraceptive YAZ (20 microg Ethinylestradiol, 3mg Drospirenone) for 13 Cycles in 670 Healthy Chinese Female Volunteers.

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Feb 2012

At a glance

  • Drugs Drospirenone/ethinylestradiol (Primary)
  • Indications Pregnancy
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Jan 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 09 Dec 2009 Planned number of patients changed from 850 to 670 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top